产品名称Magrolimab (anti-CD47), 白细胞表面抗原 CD47 抑制剂 别名莫洛利单抗 | 马格罗利单抗(抗 CD47) 英文别名5F9 | GS-4721 | Hu5F9 G4 | ONO 7913 | antigen identified by monoclonal 1D8 | Antigenic surface determinant protein OA3 | CD47 antigen (Rh-related antigen, integrin-associated signa...
关键字:Magrolimab;莫洛利单抗;2169232-81-7;Protein MER6, MER6;CD47; 公司简介 武汉佰乐博生物(Biolab Reagents)由五位毕业于华中科技大学,华中农业大学,武汉大学等知名高校,且具有二十年工作经验的生命科学领域顶级研究者创立于2021年,凭借丰富的产品开发经验,利用全球领先的技术平台,引进和整合全球高品质的蛋白、...
We have previously shown that magrolimab in combination with tumor-targeting antibodies (e.g. rituximab) further enhances magrolimab's anti-cancer effects in preclinical models and in the clinic [Advani R, et al. N Engl J Med 2018; 379:1711-1721]. We therefore hypothesized that magrolimab...
A. et al. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. J. Clin. Oncol. 38, 114–114 (2020). Article Google Scholar Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. ...
Anti-CD47 Reference Antibody (magrolimab) 中文名: 中文别名: CBNumber: CB914001935 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商1 Anti-CD47 Reference Antibody (magrolimab)化学性质 安全信息 Anti-CD47 Reference Antibody (magrolimab)性质、用途与生产工艺 ...
吉利德:2月15日,吉利德宣布已暂停在研CD47抗体药物magrolimab部分实体瘤研究的患者招募,FDA也对这些试验进行了部分临床搁置。此前,magrolimab已停止所有CD47血液瘤适应症项目,该药物在2023年7月21日宣告骨髓增生异常综合征的III期临床试验失败。 辉瑞:2024年,辉瑞公司宣布自愿从全球市场撤回其治疗镰状细胞病的药物...
The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results Blood, 134 (2019), p. 569 View PDFView articleCrossrefGoogle Scholar 41 D Cancilla, MP Rettig, JF DiPersio Targeting CXCR4 in AML and ...
The primary class of early CD47-SIRPα pathway-targeting drugs have been mAbs. Magrolimab, the most advanced anti-CD47 antibody, resulted in a high response rate in hematological tumors (complete response (CR): 53% in untreated acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), 10%...
Hu5F9-G4 (Magrolimab) is the first αCD47 that enters clinical development, although the preliminary results were encouraging, the raised side effects, especially anemia and thrombocytopenia, have attracted considerable attention due to the widespread expression of CD47 [18], [19], [20]. To ...
Antibody Type: Biosimilar Reference Antibody Applications: IHC FC Drug Development Pharmacokinetics Disease Area: Cancer Protein: IL-4RA Reactivity: Human Host Species: Chimeric Humanized Isotype: IgG4 €399 Antibody Size:Required100 μg Current Stock: ...